MedTrace Logo

The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients

NCT02850627 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-08-02

No results posted yet for this study

Summary

The purpose of this study is to test the expression of microRNAs related to the syndromes after the intervention of Tongguan capsule,preliminarily to investigate the mechanism of the effects of Tongguan capsule, and provide the biological foundation of curative effect of Tongguan capsule.

Conditions

Interventions

DRUG

Tongguan capsule

eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)

DRUG

placebo capsule

eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)

Sponsors & Collaborators

  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    lead OTHER

Principal Investigators

  • Minzhou Zhang, MD · Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine

  • Huizheng Zhu, PhD · Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-09-30
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02850627 on ClinicalTrials.gov